Regulatory Show all
June 20 | 2019

2cureX utser Dr. Henrik Harling till Chief Medical Officer

Read more
May 28 | 2019

Kommuniké från årsstämma i 2cureX AB (publ)

Read more
May 28 | 2019

Communique from the Annual General Meeting in 2cureX AB (publ)

Read more
May 28 | 2019

Kraftigt övertecknad företrädesemission i 2cureX AB

Read more
May 28 | 2019

Significantly oversubscribed rights issue in 2cureX AB

Read more
May 9 | 2019

CORRECTION: 2cureX publishes interim report for the first quarter of 2019

Read more
May 9 | 2019

Idag inleds teckningstiden i 2cureX företrädesemission

Read more
May 9 | 2019

Today, the subscription period starts in 2cureX’s rights issue

Read more
May 8 | 2019

2cureX offentliggör memorandum inför företrädesemissionen

Read more
May 8 | 2019

2cureX publishes memorandum ahead of the rights issue

Read more
May 8 | 2019

2cureX publishes interim report for the first quarter of 2019

Read more
May 8 | 2019

2cureX offentliggör delårsrapport för det första kvartalet 2019

Read more
May 7 | 2019

2cureX offentliggör årsredovisning för räkenskapsåret 2018

Read more
May 7 | 2019

2cureX publishes the annual report for the fiscal year 2018

Read more
April 24 | 2019

2cureX decides on rights issue prior to market launch of IndiTreat®

Read more
April 24 | 2019

2cureX beslutar om företrädesemission inför marknadslansering av IndiTreat®

Read more
April 4 | 2019

2cureX offentliggör kommersiellt samarbete med Gibson Oncology, USA

Read more
April 4 | 2019

2cureX announces commercial collaboration with Gibson Oncology, USA

Read more